caa a22 4500 606220984 CHVBK 20210128101126.0 cr unu---uuuuu 210128e20150501xx s 000 0 eng 10.1007/s00380-014-0484-9 doi (NATIONALLICENCE)springer-10.1007/s00380-014-0484-9 Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease [Elektronische Daten] [Daishi Fujita, Masao Takahashi, Kent Doi, Mitsuru Abe, Junichi Tazaki, Arihiro Kiyosue, Masahiro Myojo, Jiro Ando, Hideo Fujita, Eisei Noiri, Takeshi Sugaya, Yasunobu Hirata, Issei Komuro] Urinary liver-type fatty acid-binding proteins (uL-FABP) have recently been recognized as a useful biomarker for predicting contrast-induced nephropathy. Although accumulating studies have evaluated short-term outcomes, its prognostic value for long-term renal prognosis in patients undergoing coronary angiography (CAG) has not been fully examined. This study aimed to evaluate the predictive value of uL-FABP for long-term renal outcome in patients with ischemic heart disease (IHD). Consecutive 24 patients with impaired renal function (serum creatinine >1.2mg/dL) who underwent CAG were enrolled. uL-FABP was measured before CAG, 24 and 48h after CAG. The changes in estimated glomerular filtration rate (eGFR) throughout CAG and at 1year later were compared with the uL-FABP levels. The patients with a greater decrease in eGFR 1year later had higher uL-FABP levels at all points, but only the value at 48h after CAG reached statistical significance (lower vs. higher decreased eGFR group, 4.61±3.87 vs. 17.71±12.96; P<0.01). Measurement of uL-FABP at 48h after CAG (48h-uL-FABP) showed better correlation with the change in eGFR (pre-CAG uL-FABP vs. 48h-uL-FABP: R=0.27, P=0.20 vs. R=0.65, P<0.01). Moreover, the high-pre and high-48h-uL-FABP group showed a significantly larger decrease in eGFR compared with the high-pre and low-48h-uL-FABP group (change in eGFR; 8.12±4.06 vs. 1.25±2.23mL/min/1.73m2, P<0.01), although the baseline eGFR levels were similar between these two groups. In this pilot study, measurement of uL-FABP levels at 48h after CAG may be useful in detecting renal damage, and in predicting 1-year renal outcome in IHD patients undergoing CAG. Springer Japan, 2014 Urinary liver-type fatty acid-binding proteins (uL-FABP) nationallicence Renal prognosis nationallicence Coronary angiography (CAG) nationallicence Contrast-induced nephropathy (CIN) nationallicence uL-FABP : Urinary liver-type fatty acid binding protein nationallicence DM : Diabetes mellitus nationallicence CKD : Chronic kidney disease nationallicence CAG : Coronary angiography nationallicence IHD : Ischemic heart disease nationallicence CIN : Contrast-induced nephropathy nationallicence sCr : Serum creatinine nationallicence eGFR : Estimated glomerular filtration rate nationallicence Fujita Daishi Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut Takahashi Masao Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut Doi Kent Division of Nephrology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut Abe Mitsuru Department of Cardiology, Kyoto Medical Center, Kyoto, Japan aut Tazaki Junichi Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan aut Kiyosue Arihiro Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut Myojo Masahiro Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut Ando Jiro Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut Fujita Hideo Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut Noiri Eisei Division of Nephrology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut Sugaya Takeshi CMIC Company, Limited, Tokyo, Japan aut Hirata Yasunobu Tokyo Teishin Hospital, Tokyo, Japan aut Komuro Issei Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut Heart and Vessels Springer Japan 30/3(2015-05-01), 296-303 0910-8327 30:3<296 2015 30 380 https://doi.org/10.1007/s00380-014-0484-9 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00380-014-0484-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Fujita Daishi Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut NATIONALLICENCE 700 1- Takahashi Masao Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut NATIONALLICENCE 700 1- Doi Kent Division of Nephrology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut NATIONALLICENCE 700 1- Abe Mitsuru Department of Cardiology, Kyoto Medical Center, Kyoto, Japan aut NATIONALLICENCE 700 1- Tazaki Junichi Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan aut NATIONALLICENCE 700 1- Kiyosue Arihiro Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut NATIONALLICENCE 700 1- Myojo Masahiro Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut NATIONALLICENCE 700 1- Ando Jiro Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut NATIONALLICENCE 700 1- Fujita Hideo Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut NATIONALLICENCE 700 1- Noiri Eisei Division of Nephrology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut NATIONALLICENCE 700 1- Sugaya Takeshi CMIC Company, Limited, Tokyo, Japan aut NATIONALLICENCE 700 1- Hirata Yasunobu Tokyo Teishin Hospital, Tokyo, Japan aut NATIONALLICENCE 700 1- Komuro Issei Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, 113-8655, Tokyo, Japan aut NATIONALLICENCE 773 0- Heart and Vessels Springer Japan 30/3(2015-05-01), 296-303 0910-8327 30:3<296 2015 30 380